Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that its Alere™ i Influenza A & B 2 test has received 510(k) marketing...
Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced the U.S. Department of Justice (the "DOJ") has...
Alere Inc. (NYSE: ALR) announced today that Abbott's acquisition of Alere is intended to close on October 3, 2017. The announcement follows receipt...
Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached an agreement in principle to...
Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that it has reached a settlement with the United...
Alere Inc. (NYSE: ALR) ("Alere"), today announced that it has submitted written notice to the New York Stock Exchange (the "NYSE") of its intention...
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual...
Alere Inc. (NYSE: ALR) ("Alere" or the "Company"), a global leader in rapid diagnostic tests, today is announcing the following, and will also be...
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced its financial results for the second quarter ended June 30, 2017....
Immunalysis Corporation, a division of Alere Inc. (NYSE: ALR), today announced that its SEFRIA™ Fentanyl Urine Enzyme Immunoassay has been granted...
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced the availability of its point-of-care Alere iCup® Rx Drug Screen, a...
Alere Inc. (NYSE: ALR) (the "Company"), a global leader in rapid diagnostic tests, today announced that its shareholders have voted to approve the...
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced its financial results for the first quarter ended March 31, 2017....
Alere Inc. (NYSE: ALR) (the "Company") announced today the termination of the previously announced consent solicitations relating to the Company's...
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced that it has filed its Form 10-K and reported its financial results ...
Alere Inc. (NYSE: ALR) (the "Company") announced today the commencement of additional consent solicitations relating to the Company's 6.500% Senior...
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, today announced certain preliminary unaudited financial information for the fourth ...
Alere Inc. (NYSE: ALR) (the "Company") announced today the successful completion of the previously announced consent solicitations relating to the...
Alere Inc. (NYSE: ALR) (the "Company") announced today certain modifications to the previously announced consent solicitations relating to the...
Alere Inc. (NYSE: ALR) (the "Company") announced today the commencement of consent solicitations relating to the Company's 6.500% Senior Subordinated ...
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced the launch of its Alere™ Malaria Ag P.f, a major technological...
Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, today announced that its Alere™ Reader, a diagnostic analyzer that can be used in both...
Alere Inc. (NYSE: ALR) (the "Company") announced today that, as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.